产品
编 号：F066819
分子式：C8H15NO2
分子量：157.21
分子式：C8H15NO2
分子量：157.21
产品类型
规格
价格
是否有货
500mg
160
In-stock
5g
400
In-stock
10g
480
In-stock
结构图
CAS No: 1197-18-8
产品详情
生物活性：
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .
体内研究：
Tranexamic acid (100 mg/kg，静脉注射，每天两次，连续 3-28 天) 促进了创伤性脑损伤后纤溶酶原缺陷小鼠更强大的免疫激活。Tranexamic acid (750 mg/kg，口服，每天 1 次，连续 20 天) 可减少肥大细胞的增殖，增加成纤维细胞的增殖，从而改善小鼠皮肤干燥引起的皱纹。Animal Model:Traumatic brain injury (TBI) mice
Dosage:100 mg/kg
Administration:Intravenous injection (i.v.)
Result:Inhibited local plasmin formation and fibrinolysis.Impacts on the local immune response following TBI.Did not enhance reactivity of cervical lymph node (cLN) cells to central nervous system (CNS) antigens.Influences the cellular immune profile of peripheral lymph nodes.Reduced microglial and macrophage activation.
Animal Model:Skin dryness induced wrinkles mice
Dosage:750 mg/kg
Administration:Oral
Result:Resulted in the amelioration of transepidermal water loss (TEWL) and moisture retention.Suppressed the generation of wrinkles.Inhibited plasma concentrations of adrenocorticotropic hormone (ACTH), corticosterone, and IgE.Suppressed proliferation of mast cells.
体外研究：
Tranexamic acid (20-100 μg/mL, 24 h) 通过增强线粒体呼吸，抑制损伤相关分子模式释放，改善人脐静脉内皮细胞 (HUVECs) 和人动脉内皮细胞 (HAECs) 的毛细血管完整性来减轻严重创伤的影响。Tranexamic acid (0.2-5 mM, 30 min) 抑制 MDA-MB-231 BAG 乳腺癌细胞的迁移。
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .
体内研究：
Tranexamic acid (100 mg/kg，静脉注射，每天两次，连续 3-28 天) 促进了创伤性脑损伤后纤溶酶原缺陷小鼠更强大的免疫激活。Tranexamic acid (750 mg/kg，口服，每天 1 次，连续 20 天) 可减少肥大细胞的增殖，增加成纤维细胞的增殖，从而改善小鼠皮肤干燥引起的皱纹。Animal Model:Traumatic brain injury (TBI) mice
Dosage:100 mg/kg
Administration:Intravenous injection (i.v.)
Result:Inhibited local plasmin formation and fibrinolysis.Impacts on the local immune response following TBI.Did not enhance reactivity of cervical lymph node (cLN) cells to central nervous system (CNS) antigens.Influences the cellular immune profile of peripheral lymph nodes.Reduced microglial and macrophage activation.
Animal Model:Skin dryness induced wrinkles mice
Dosage:750 mg/kg
Administration:Oral
Result:Resulted in the amelioration of transepidermal water loss (TEWL) and moisture retention.Suppressed the generation of wrinkles.Inhibited plasma concentrations of adrenocorticotropic hormone (ACTH), corticosterone, and IgE.Suppressed proliferation of mast cells.
体外研究：
Tranexamic acid (20-100 μg/mL, 24 h) 通过增强线粒体呼吸，抑制损伤相关分子模式释放，改善人脐静脉内皮细胞 (HUVECs) 和人动脉内皮细胞 (HAECs) 的毛细血管完整性来减轻严重创伤的影响。Tranexamic acid (0.2-5 mM, 30 min) 抑制 MDA-MB-231 BAG 乳腺癌细胞的迁移。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备